Research
Hormonal
In the obesity cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -12.3% to -16.2%, compared to -2.5% with placebo.
Maridebart cafraglutide may be an effective treatment option for weight loss in individuals with obesity.
StrongSupportsmedium confidence
In the obesity cohort... the mean percent change in body weight from baseline to week 52... ranged from -12.3%... to -16.2%... with placebo.
Why this rating
Based on the phase 2, double-blind, randomized, placebo-controlled trial design.
Source
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
Ania M. Jastreboff et al. · New England Journal of Medicine · 2025
DOI 10.1056/nejmoa2504214
rct · n=592Cited 55×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In the obesity-diabetes cohort, maridebart cafraglutide resulted in a mean percent change in body weight from baseline to week 52 ranging from -8.4% to -12.3%, compared to -1.7% with placebo.Strong
- Gastrointestinal adverse events were common with maridebart cafraglutide, although less frequent with dose escalation and a lower starting dose.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →